Previous Next Low-value Care Evidence conflicts over efficacy of monoclonal antibodies in severe COVID Abstract: "We are left with evidence of benefit from interleukin-6 inhibitors, at least under some circumstances." Publication: CIDRAP Date Published: February 26, 2021 Author(s): Mary Van Beusekom View This Resource